gefitinib

Related by string. Gefitinib * * gefitinib Iressa . Iressa gefitinib *

Related by context. All words. (Click for frequent words.) 76 erlotinib 72 imatinib 71 chlorambucil 71 bortezomib 71 sorafenib 71 docetaxel 71 gemcitabine 71 dasatinib 71 EGFR mutations 71 pemetrexed 71 Taxotere ® 70 trastuzumab 70 vandetanib 70 cetuximab 69 sunitinib 69 gefitinib Iressa 69 metastatic RCC 69 Gefitinib 69 temsirolimus 69 carboplatin 69 FOLFOX4 69 Erlotinib 69 advanced NSCLC 68 pegylated liposomal doxorubicin 68 HER2 positive metastatic breast 68 neoadjuvant chemotherapy 68 sorafenib Nexavar 68 trabectedin 68 FOLFIRI 68 plus dexamethasone 68 Vectibix 67 carboplatin paclitaxel 67 bevacizumab 67 dacarbazine 67 EGFR mutation 67 Fludara 67 cisplatin 67 EGFR inhibitors 67 Doxil ® 67 decitabine 67 metastatic renal cell carcinoma 67 mRCC 67 Tarceva 67 mycophenolate mofetil 67 heavily pretreated 67 raltegravir 67 nilotinib 67 NSCLC 67 bendamustine 66 erlotinib Tarceva 66 tocilizumab 66 rituximab 66 chemoradiation 66 Velcade bortezomib 66 IRESSA 66 adjuvant therapy 66 azacitidine 66 Amrubicin 66 lamivudine 66 Targretin 66 seliciclib 66 EGFR TKIs 66 EGFR tyrosine kinase inhibitors 66 panitumumab 66 Bortezomib 66 anti TNF 65 APTIVUS r 65 FOLFOX 65 posaconazole 65 enzastaurin 65 zoledronic acid 65 TNF inhibitor 65 Trastuzumab 65 PXD# 65 adriamycin 65 infliximab 65 imetelstat 65 taxane therapy 65 lapatinib 65 pertuzumab 65 adalimumab 65 capecitabine 65 Tarceva erlotinib 65 imatinib Gleevec 65 recurrent GBM 64 entecavir 64 bevacizumab Avastin ® 64 Herceptin trastuzumab 64 topotecan 64 temozolomide 64 platinum refractory 64 Platinol 64 Tamibarotene 64 cediranib 64 gemcitabine chemotherapy 64 mitoxantrone 64 EGFR TKI 64 Pemetrexed 64 irinotecan 64 chemoradiotherapy 64 OPAXIO 64 mapatumumab 64 mCRC patients 64 adjuvant chemotherapy 64 darunavir 64 vorinostat 64 VIDAZA 64 DMARDs 64 SCH # 64 erlotinib Tarceva ® 64 amrubicin 64 peginterferon 64 T#I [002] 64 recurrent NSCLC 64 advanced hepatocellular carcinoma 64 letrozole 64 tyrosine kinase inhibitors 64 etanercept 64 TACE 64 thalidomide Thalomid 64 XELOX 64 idarubicin 64 sorafenib Nexavar ® 64 ixabepilone 64 DMARD 64 mCRC 64 Iressa 63 ASA# 63 vinorelbine 63 Tavocept 63 afatinib 63 docetaxel chemotherapy 63 Vectibix monotherapy 63 neoadjuvant treatment 63 ZOLINZA 63 oxaliplatin 63 IFN α 63 metastatic colorectal cancer 63 goserelin 63 pomalidomide 63 PREZISTA r 63 vicriviroc 63 relapsed ovarian cancer 63 ritonavir boosted 63 abiraterone 63 Dasatinib 63 Torisel 63 KRAS mutations 63 gemcitabine Gemzar 63 YONDELIS 63 fulvestrant 63 Traficet EN 63 PegIntron 63 TKIs 63 chemotherapy regimens 63 adefovir 63 anastrozole 63 nelfinavir 63 HER2 negative 63 iniparib 63 HRPC 63 exemestane 63 virologic failure 63 adjuvant radiotherapy 63 trastuzumab Herceptin 63 Irinotecan 63 taxane 63 cilengitide 63 axitinib 63 FOLFIRINOX 63 idraparinux 63 malignant pleural mesothelioma 63 cabazitaxel 63 preoperative chemotherapy 63 TNF inhibitors 63 bevacizumab Avastin 63 Bevacizumab 63 tipranavir 63 ZD# [001] 63 patients evaluable 63 Aflibercept 63 clodronate 63 ACTEMRA TM 63 SCCHN 63 CANCIDAS 63 DOXIL 63 adecatumumab 63 stage IIIB 63 neoadjuvant therapy 63 elotuzumab 63 pancreatic adenocarcinoma 63 CIMZIA ™ 63 abiraterone acetate 63 castration resistant prostate cancer 63 5FU 62 liver metastases 62 oblimersen 62 virologic response 62 LEXIVA r 62 nab paclitaxel 62 standard chemotherapy regimen 62 LY# [003] 62 KRAS status 62 Gleevec resistant 62 olaparib 62 liposomal doxorubicin 62 Ceplene/IL-2 62 chemotherapeutic agents 62 chronic lymphocytic leukemia CLL 62 EGFR mutation positive 62 Hycamtin 62 Tarceva TM 62 fluorouracil 62 antiangiogenic therapy 62 imatinib therapy 62 HBeAg positive 62 ribavirin RBV 62 Gemcitabine 62 peginterferon alfa 2a 62 ZACTIMA 62 MGd 62 docetaxel Taxotere 62 TORISEL 62 tenofovir emtricitabine 62 VAPRISOL 62 bortezomib Velcade 62 mg kg dose 62 ustekinumab 62 micafungin 62 teriflunomide 62 proteasome inhibitor 62 peg IFN 62 Doxil 62 Flu Cy 62 EpCAM 62 CIMZIA TM 62 5-FU/LV 62 infusional 5-FU/LV 62 hepatocellular carcinoma HCC 62 pegylated interferon alpha 62 Docetaxel 62 APTIVUS 62 irinotecan chemotherapy 62 interferon alfa 62 paclitaxel 62 rilpivirine 62 NNRTIs 62 Velcade 62 evaluable patients 62 biologic therapy 62 doripenem 62 talabostat 62 eplerenone 62 stage IIIb IV 62 tamoxifen therapy 62 Taxol ® 62 alpha interferon 62 MabCampath 62 relapsed SCLC 62 enfuvirtide 62 alkylating agents 62 KRAS wild 62 anthracyclines 62 anti leukemic 62 squamous histology 62 cetuximab Erbitux 62 doxorubicin 62 pioglitazone 62 AVASTIN 62 imatinib Gleevec ® 61 Capecitabine 61 IFN beta 61 postoperative chemotherapy 61 Vandetanib 61 febuxostat 61 recurrent glioblastoma multiforme 61 AEG# 61 lenalidomide 61 taxanes 61 taxane chemotherapy 61 5 FU 61 refractory CLL 61 concurrent chemoradiation 61 abatacept 61 paclitaxel Taxol 61 panitumumab Vectibix 61 cisplatin chemotherapy 61 fluoropyrimidine 61 DAPT 61 unresectable stage 61 T DM1 61 pegylated interferon alfa 2a 61 ISENTRESS 61 glufosfamide 61 azathioprine 61 placebo dexamethasone 61 Dapagliflozin 61 G CSF 61 imatinib resistant 61 antitumor activity 61 HGS ETR1 61 differentiated thyroid 61 Taxotere 61 Fludara ® 61 bosutinib 61 metastatic HRPC 61 Avastin bevacizumab 61 Exemestane 61 Xanafide 61 depsipeptide 61 docetaxel Taxotere R 61 celecoxib 61 Copegus ribavirin 61 angiogenesis inhibitor 61 pegylated interferons 61 aflibercept 61 proteasome inhibitor bortezomib 61 nonresponders 61 NNRTI 61 low dose cytarabine 61 KRAS mutations occur 61 monotherapy 61 TREANDA 61 Fulvestrant 61 superficial bladder cancer 61 metastatic castration resistant 61 bicalutamide 61 cytotoxic chemotherapy 61 dacarbazine DTIC 61 tamoxifen 61 fluvastatin 61 fondaparinux 61 surrogate endpoint 61 hormone refractory prostate cancer 61 tumor recurrence 61 RG# [001] 61 metastatic CRC 61 unresectable 61 alteplase 61 tiotropium 61 trastuzumab Herceptin R 61 metastatic hormone refractory 61 neoadjuvant 61 VELCADE melphalan 61 Neulasta ® 61 Aromasin 61 rituximab Rituxan 61 recurrent ovarian cancer 61 FluCAM 61 achieved sustained virological 61 capecitabine Xeloda 61 comparator arm 61 IMGN# 61 daunorubicin 61 BAY #-# 61 phase IIb clinical 61 GVAX 61 abacavir lamivudine 61 eribulin 61 Pfizer Sutent 61 dasatinib Sprycel 61 follicular NHL 61 Bezielle 61 FOLFOX6 61 pazopanib 61 Imatinib 61 ticagrelor 61 complete cytogenetic response 61 evaluating tivozanib 61 dose cytarabine 61 Peginterferon 61 PKC# 61 YERVOY 61 HBeAg negative patients 61 imatinib mesylate Gleevec 61 plus prednisone 61 imatinib mesylate 61 etoposide 61 NRTIs 61 glatiramer acetate 60 heavily pretreated patients 60 interferon ribavirin 60 BRAF mutation 60 CA4P 60 EGFR 60 median PFS 60 trastuzumab Herceptin ® 60 HBeAg positive patients 60 xenograft models 60 leukemia CLL 60 NATRECOR R 60 5 fluorouracil 60 free survival PFS 60 peginterferon alfa 2b 60 bexarotene 60 noninferiority 60 Rituximab 60 teriparatide 60 endocrine therapy 60 Gemzar ® 60 Ixempra 60 pegylated interferon alfa 2b 60 bosentan 60 MetMAb 60 receptor tyrosine kinase inhibitor 60 anticancer therapies 60 multiple myeloma MM 60 tyrosine kinase inhibitor 60 Nexavar ® 60 non squamous NSCLC 60 active comparator 60 colorectal liver metastases 60 INTELENCE 60 PRT# 60 viral kinetics 60 pegylated interferon 60 nitazoxanide 60 K ras mutations 60 trabedersen 60 oral rivaroxaban 60 cilostazol 60 docetaxel Taxotere ® 60 PLX# 60 Sorafenib 60 candesartan 60 standard chemotherapy regimens 60 Ceflatonin 60 CoFactor 60 androgen deprivation 60 ximelagatran 60 locoregional 60 fludarabine 60 HuMax CD4 60 BARACLUDE R 60 Navelbine ® 60 adjuvant radiation 60 AGILECT R 60 Halaven 60 APTIVUS R 60 fluconazole 60 melphalan prednisone 60 dexamethasone Decadron 60 itraconazole 60 Lenalidomide 60 irbesartan 60 complete cytogenetic 60 sunitinib malate 60 STELARA 60 protease inhibitor PI 60 PegIFN RBV 60 splenectomized patients 60 alkylating agent 60 valsartan 60 Cytoxan 60 romidepsin 60 visilizumab 60 rFVIIa 60 Hepsera 60 non squamous 60 sunitinib Sutent 60 EGFR tyrosine kinase inhibitor 60 voriconazole 60 metformin 60 cell lymphoma CTCL 60 allopurinol 60 mitomycin 60 AMN# [001] 60 tanespimycin 60 Revlimid lenalidomide 60 refractory AML 60 sorafenib tablets 60 dasatinib Sprycel ® 60 Zolinza 60 FOLOTYN 60 OncoVEX GM CSF 60 ErbB2 positive 60 dacarbazine chemotherapy 60 MEK inhibitors 60 paricalcitol 60 risedronate 60 prospectively defined 60 AP# [003] 60 figitumumab 60 Elitek 60 LMWH 60 locoregional recurrence 60 linezolid 60 abciximab 60 cetuximab Erbitux ® 60 flavopiridol 60 ASCT 60 Telbivudine 60 paclitaxel cisplatin 60 interferon therapy 60 metaglidasen 60 ganetespib 60 relapsed multiple myeloma 60 Erbitux 60 Neoadjuvant 60 Pegintron 60 Tykerb 60 HBeAg seroconversion 60 durable remissions 60 chemotherapeutic drug 60 velafermin 60 picoplatin 60 cetuximab Erbitux R 60 lapatinib Tykerb 60 LY# [002] 60 lenalidomide Revlimid R 60 beta2 agonist 60 Navelbine 60 sustained virologic response 60 galiximab 60 Alemtuzumab 60 hormonal therapies 60 TEMODAL 60 tipranavir ritonavir 60 perifosine 59 HCV SPRINT 59 dabigatran etexilate 59 EGFr 59 bezafibrate 59 lenalidomide dexamethasone 59 evaluable 59 HER2 positive 59 nilotinib Tasigna 59 TYKERB 59 Imprime PGG 59 FOLPI 59 KRAS mutation 59 trans retinoic acid 59 Symadex 59 Nexavar 59 FTY# 59 GRASPA ® 59 Paraplatin ® 59 gemcitabine carboplatin 59 distant metastasis 59 Carfilzomib 59 TroVax ® 59 rizatriptan 59 XYOTAX 59 olmesartan 59 flutamide 59 azacytidine 59 palonosetron 59 peginterferon alfa 2a Pegasys 59 estramustine 59 metastatic GIST 59 XGEVA 59 telmisartan 59 ACZ# 59 antitumor effect 59 cytotoxic therapy 59 Cethromycin 59 Celecoxib 59 belinostat 59 Mylotarg 59 ceftazidime 59 lopinavir r 59 oral Xeloda 59 tacrolimus ointment 59 dexrazoxane 59 plus gemcitabine 59 paclitaxel carboplatin 59 efalizumab 59 Camptosar 59 endocrine therapies 59 pCR 59 advanced adenomas 59 anidulafungin 59 brain metastases 59 vinca alkaloid 59 AZT zidovudine Retrovir 59 clopidogrel 59 plus ribavirin 59 hepatocellular carcinoma 59 cinacalcet 59 BRAF inhibitor 59 AEGR 59 adalimumab Humira 59 BARACLUDE ® 59 CBLC# 59 calcitriol 59 carfilzomib 59 Gleevec imatinib 59 golimumab 59 Iressa gefitinib 59 CHOP chemotherapy 59 Hepatocellular Carcinoma HCC 59 Pertuzumab 59 hepatocellular cancer 59 COPAXONE R 59 edoxaban 59 stage IIIB IV 59 HER2 positive breast cancer 59 CMV disease 59 levosimendan 59 Gleevec 59 indolent NHL 59 Reverset 59 gastrointestinal stromal tumors 59 ipilimumab 59 β blockers 59 randomized Phase III 59 Amplimexon 59 custirsen 59 mTOR inhibitor 59 Cisplatin 59 Proxinium TM 59 darunavir ritonavir 59 Peg IFN 59 nucleoside analogue 59 tarenflurbil 59 distant metastases 59 Fludarabine 59 Genasense 59 ancrod 59 interferon gamma 1b 59 ERBITUX 59 Pegylated Interferon 59 GRN#L 59 hypomethylating agents 59 Taxotere R 59 antiplatelet therapy 59 prucalopride 59 metastatic renal cell 59 pegfilgrastim 59 SPRYCEL 59 CsA 59 carvedilol 59 NXL# 59 IDH1 mutation 59 KRAS mutant tumors 59 interferon beta 1a 59 Myelodysplastic Syndrome MDS 59 EGF receptor 59 HNSCC 59 imipenem 59 chemotherapeutic agent 59 zalutumumab 59 uric acid lowering 59 HGS# 59 dose dexamethasone 59 virologic 59 TMC# [001] 59 Femara 59 tumor shrinkage 59 resectable 59 ELOXATIN 59 gemcitabine cisplatin 59 bleomycin 59 antiplatelet agent 59 metastatic colorectal 59 adjuvant therapies 59 fosamprenavir 59 low dose dexamethasone 59 hormone receptor positive 59 VEGFR2 59 dutasteride 59 Solid Tumors 59 gadobutrol 59 interferon beta therapy 59 telaprevir dosed 59 brentuximab vedotin 59 mTOR inhibitors 59 NNRTI resistance 59 sapacitabine 59 Subgroup analysis 59 CTAP# Capsules 59 insulin glargine 59 refractory multiple myeloma 59 REMICADE ® 59 TNF antagonist 59 Faslodex 59 ofatumumab 59 TNF alpha inhibitor 59 celgosivir 59 Boceprevir 59 leukemia AML 59 microbiological eradication 59 tesmilifene 59 epirubicin 59 anti EGFR antibody 59 biochemical recurrence 59 Betaferon ® 59 refractory NSCLC 59 prostate carcinoma 59 chemotherapeutic drugs 59 Taxotere docetaxel 59 tamsulosin 59 Pegasys ® 59 Virologic 59 mutated KRAS gene 59 vemurafenib 59 chemotherapy docetaxel 59 Metastatic Colorectal Cancer 59 telbivudine 59 MET amplification 59 docetaxel prednisone 58 intravenous bisphosphonates 58 motesanib 58 apremilast 58 virological response 58 TOP2A 58 Alimta 58 direct thrombin inhibitors 58 Campath alemtuzumab 58 Temsirolimus 58 TELINTRA 58 INCB# [003] 58 remission induction 58 paclitaxel eluting stents 58 XmAb# 58 achieve sustained virologic 58 Mitoxantrone 58 Insegia 58 follicular lymphoma 58 pentamidine 58 mutated KRAS 58 atazanavir 58 refractory chronic myeloid 58 huC# DM4 58 interferon IFN 58 gemifloxacin 58 Jevtana 58 amoxicillin clavulanate 58 resistant ovarian cancer 58 ibandronate 58 ponatinib 58 insulin detemir 58 Aptivus ® 58 CYT# 58 SPRYCEL ® 58 DU #b 58 HCV genotype 58 metastatic breast cancer 58 fallopian tube cancers 58 sipuleucel T 58 zoledronate 58 RoACTEMRA 58 Sprycel 58 Everolimus 58 WT1 58 follicular lymphomas 58 Tesmilifene 58 intravenous dosing 58 immunomodulator 58 MDV# 58 paclitaxel chemotherapy 58 eosinophilic asthma 58 Pralatrexate 58 lixisenatide 58 darapladib 58 vancomycin 58 panobinostat 58 diagnosed multiple myeloma 58 mcg albinterferon alfa 2b 58 dexamethasone 58 CR# vcMMAE 58 HCV RESPOND 2 58 cisplatin resistant 58 GW# [003] 58 chemotherapies 58 alpha 2a 58 clofarabine 58 Arixtra 58 advanced unresectable 58 PD LID 58 Sym# 58 MAGE A3 ASCI 58 DAVANAT 58 adjuvant tamoxifen 58 telcagepant 58 relapsed refractory 58 Natalizumab 58 amifostine 58 Azedra 58 SIR Spheres 58 follicular lymphoma FL 58 Laquinimod 58 ritonavir boosted atazanavir 58 regorafenib 58 Tolvaptan 58 TAXUS Liberte Stent 58 etravirine 58 IMC A# 58 atrasentan 58 Rituxan rituximab 58 TNF antagonists 58 invasive candidiasis 58 mecamylamine 58 EFAPROXYN 58 aprepitant 58 GFT# 58 Taxotere chemotherapy 58 chronic myeloid leukemia CML 58 anakinra 58 anthracycline 58 PF # [001] 58 dacetuzumab 58 Onconase 58 FOLFIRI alone 58 lacosamide 58 masitinib 58 satraplatin 58 prostate cancer CRPC 58 alvespimycin 58 Platinol ® cisplatin 58 mutational status 58 IMA# 58 Hycamtin ® 58 gastrointestinal stromal tumor GIST 58 VaD 58 BRIM2 58 lupus nephritis 58 Epratuzumab 58 pitavastatin 58 SRT# [003] 58 boosted protease inhibitor 58 REYATAZ R 58 antiandrogen 58 Anthracycline 58 elagolix 58 eribulin mesylate 58 oral Hycamtin 58 Eribulin 58 PEG IFN 58 Alkeran 58 Candesartan 58 milatuzumab 58 anthracycline taxane 58 methotrexate 58 dosage regimens 58 MIRCERA 58 Atacand 58 5 Fluorouracil 58 Doxorubicin 58 tirofiban 58 XL# [003] 58 GnRH agonist 58 CYT# potent vascular disrupting 58 paroxysmal AF 58 alpha blocker 58 placebo controlled clinical 58 mirtazapine 58 methotrexate monotherapy 58 elacytarabine 58 androgen independent 58 eculizumab 58 bortezomib refractory 58 Epivir 58 romiplostim 58 rNAPc2 58 platelet inhibitor 58 Trabectedin 58 Glufosfamide 58 HuMax EGFr 58 cisplatin vinorelbine 58 entinostat 58 PEG interferon 58 HER2 positive tumors 58 Genasense ® 58 ABVD 58 Interferon alfa 58 paclitaxel Taxol ® 58 Elotuzumab 58 APOPTONE 58 chemotherapeutic regimens 58 oxycodone CR 58 HCV genotype 1 58 antithrombotic 58 Xeloda 58 ZYVOX 58 INCB# [001] 58 TELCYTA 58 JAK inhibitors 58 Castration Resistant Prostate Cancer 58 pancreatic neuroendocrine tumors 58 tigecycline 58 vismodegib 58 dalteparin 58 tolvaptan 58 gastric cancers 58 pan HDAC inhibitor 58 curative resection 58 interferon 58 PARP inhibition 58 desvenlafaxine succinate 58 Carboplatin 58 Telintra 58 biliary tract cancer 58 hormonal therapy 58 EGFR expressing mCRC 58 Apaziquone 58 colorectal cancer liver metastases 58 GvHD 58 forodesine 58 B CLL 58 MMP inhibitors 58 HER2 positive cancers 58 citalopram 58 Pazopanib 58 FLT3 58 Nexavar sorafenib 58 basal cell carcinoma BCC 58 Aplidin 58 NovoTTF 58 FK# 58 sitagliptin 58 cytogenetic response 58 recurrent GBM patients 58 cell lung cancer 58 untreated multiple myeloma 58 Allovectin 7 ® 58 relapsed MM 58 Tyrima 58 PEG SN# 58 medically inoperable 58 fibrinolytic 58 RECIST Response Evaluation Criteria 58 BMS # 58 Thal Dex 58 ELACYT 58 metastatic malignant 58 tiotropium bromide 58 Tarvacin 58 pamidronate 58 Vidaza azacitidine 58 antitumor 58 etanercept Enbrel 58 HCV infected 58 sirolimus 58 caspofungin 58 GP IIb IIIa inhibitors 58 Lamivudine 58 interferon beta 58 ketoconazole 58 laquinimod 58 CD3 monoclonal antibody 58 SERMs 58 Abatacept 58 Hematologic 58 alfa 2a 58 iloprost 58 bivalirudin 58 Panzem R NCD 58 N acetylcysteine 58 pancreatic NET 57 mg BID 57 mg dose 57 mcg kg 57 HBeAg negative 57 Median survival 57 CIPN 57 Combination therapy 57 Nilotinib 57 virologic responses 57 OHR/AVR# 57 PREZISTA ritonavir 57 complete remissions 57 Actemra 57 IRX 2 57 Paclitaxel 57 anticancer agent 57 Free Survival PFS 57 solid tumors 57 corticosteroid therapy 57 prednisone prednisolone 57 histologies 57 metastatic malignant melanoma 57 resminostat 57 candesartan cilexetil 57 H. pylori eradication 57 strontium ranelate 57 Entecavir 57 Debio 57 HBeAg 57 relapsing MS 57 nucleoside analogues 57 HuLuc# 57 PSMA ADC 57 Kaplan Meier analysis 57 PEG INTRON 57 baminercept 57 rosuvastatin #mg 57 OXi# 57 Lubiprostone 57 chemotherapy gemcitabine 57 palifermin 57 chemopreventive agent 57 disease progression 57 refractory metastatic 57 gastric cancer 57 Vaprisol 57 rhIL 7 57 PROCHYMAL 57 cytarabine

Back to home page